Skip to Main Content

A three-year-old gene therapy startup from Florida is relaunching Thursday with an infusion of health care investor cash and a chief executive officer recruited from Sarepta Therapeutics.

AavantiBio will use $107 million in new Series A financing to fund the development of an experimental gene therapy to treat patients with Friedreich’s Ataxia, a rare, inherited disease that causes damage to the central nervous system and heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!